PCVX to release OPUS-1 phase III data for VAX-31 by end-October
Vaxcyte said OPUS-1 phase III data for VAX-31 will target broader pneumococcal coverage and an improved immune response and is due for release by end of October.
OPUS-1 phase III data for VAX-31, aimed at broader pneumococcal coverage and a stronger immune response, is set for release by end-October. Commercial and manufacturing plans are already in place, with attention on addressing current market trade-offs and scaling after the data. Based on Vaxcyte, Inc. [PCVX] 1…